Accessibility Menu
 
Oramed Pharmaceuticals logo

Oramed Pharmaceuticals

(NASDAQ) ORMP

Current Price$3.54
Market Cap$142.78M
Since IPO (2004)+1,983%
5 Year-61%
1 Year+78%
1 Month+4%

Oramed Pharmaceuticals Financials at a Glance

Market Cap

$142.78M

Revenue (TTM)

$2.00M

Net Income (TTM)

$75.32M

EPS (TTM)

$1.49

P/E Ratio

2.38

Dividend

$0.00

Beta (Volatility)

1.16 (Average)

Price

$3.54

Volume

1,230

Open

$3.49

Previous Close

$3.54

Daily Range

$3.49 - $3.55

52-Week Range

$1.98 - $3.76

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Oramed Pharmaceuticals

Industry

Pharmaceuticals

Employees

13

CEO

Nadav Kidron, MBA

Headquarters

New York City, NY 10036, US

ORMP Financials

Key Financial Metrics (TTM)

Gross Margin

1%

Operating Margin

-8%

Net Income Margin

38%

Return on Equity

37%

Return on Capital

-19%

Return on Assets

77%

Earnings Yield

42.02%

Dividend Yield

0.00%

Payout Ratio

14.43%

Stock Overview

Market Cap

$142.78M

Shares Outstanding

40.45M

Volume

1.23K

Short Interest

0.00%

Avg. Volume

191.13K

Financials (TTM)

Gross Profit

$13.00K

Operating Income

$15.09M

EBITDA

$15.09M

Operating Cash Flow

$9.14M

Capital Expenditure

$9.00K

Free Cash Flow

$9.15M

Cash & ST Invst.

$51.36M

Total Debt

$825.00K

Oramed Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$61.00K

+296.8%

Gross Margin

0.00%

N/A

Market Cap

$142.78M

N/A

Market Cap/Employee

$10.98M

N/A

Employees

13

N/A

Net Income

$21.28M

+308.9%

EBITDA

$83.26M

-753.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$50.54M

-64.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$540.00K

+246.2%

Short Term Debt

$285.00K

+31.9%

Return on Assets

77.18%

N/A

Return on Invested Capital

-19.22%

N/A

Free Cash Flow

$4.05M

-108.2%

Operating Cash Flow

$4.05M

-109.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CNTBConnect Biopharma Holdings Limited
$2.82+1.44%
KLRSKalaris Therapeutics Inc
$6.30+3.79%
IFRXInflaRx N.V.
$1.00-2.91%
COYACoya Therapeutics, Inc.
$4.17-7.95%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$128.06-0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.61+0.02%
NOKNokia
$9.46-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$6.44-0.05%

Questions About ORMP

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.